1
|
Vitetta GM, Ravera A, Mensa G, Fuso L, Neri P, Carriero A, Cirillo S. Actual role of color-doppler high-resolution neck ultrasonography in primary hyperparathyroidism: a clinical review and an observational study with a comparison of 99mTc-sestamibi parathyroid scintigraphy. J Ultrasound 2019; 22:291-308. [PMID: 30357759 PMCID: PMC6704209 DOI: 10.1007/s40477-018-0332-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2018] [Accepted: 10/11/2018] [Indexed: 01/15/2023] Open
Abstract
PURPOSE Primary hyperparathyroidism (PHPT) is a frequent endocrine pathology that has surgical treatment as its only decisive measure. High-Resolution Neck Ultrasonography with color-Doppler (CDHR-NUS) and 99mTechnetium-SestaMIBI Parathyroid Scintigraphy (99mTc-MIBI PS) are the two instrumental exams more commonly used in the preoperatory localization of pathologic parathyroids. The aim of this observational study was to outline-in accordance with the latest scientific literature-the precise role of CDHR-NUS in the environment of PHPT, comparing it with that of Parathyroid Scintigraphy. METHODS 136 patients operated on for PHPT and underwent CDHR-NUS and 99mTc-MIBI PS preoperatively. The CDHR-NUS was carried out by an expert medical sonographer. The results of the two methods were compared between each other and with the results of the operative act for the evaluation of accordance and diagnostic performances. RESULTS PHPT is prevalently due to monoglandular pathology (SGD). The parallel use of CDHR-NUS and of 99mTc-MIBI PS does not determine a significant increase in diagnostic accuracy. The preoperative accordance evaluation between the two methods does not exclude the presence of multiglandular pathology (MGD) with certainty. CONCLUSIONS CDHR-NUS is an accurate as well as cost-effective method; its role as a main and eventual unique preoperative localization method in patients affected by PHPT is confirmed. In the presence of expert medical sonographers, the sequential use of the two methods is retained correct and their use in parallel is neither justified nor cost-effective. The preoperative accordance evaluation between the two methods is neither necessary nor indispensable.
Collapse
Affiliation(s)
- Giovanni Mariano Vitetta
- S.C. Radiodiagnostica, Azienda Ospedaliera Ordine Mauriziano di Torino, Largo Turati, 62-10128, Turin, Italy.
| | - Alberto Ravera
- S.S. Chirurgia della Tiroide, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy
| | - Giovanni Mensa
- S.S. Chirurgia della Tiroide, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy
| | - Luca Fuso
- Dipartimento di Scienze Chirurgiche, Università di Torino, Turin, Italy
| | - Pierluigi Neri
- S.C.D.U. di Radiodiagnostica e Interventistica, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Novara, Italy
| | - Alessandro Carriero
- S.C.D.U. di Radiodiagnostica e Interventistica, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Novara, Italy
| | - Stefano Cirillo
- S.C. Radiodiagnostica, Azienda Ospedaliera Ordine Mauriziano di Torino, Largo Turati, 62-10128, Turin, Italy
| |
Collapse
|
2
|
Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, Berdelou A, Hadoux J, Hescot S, Remy H, Baudin E, Schlumberger M, Deandreis D. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. Eur J Nucl Med Mol Imaging 2018; 45:1772-1780. [PMID: 29680989 DOI: 10.1007/s00259-018-4018-z] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Accepted: 04/10/2018] [Indexed: 12/13/2022]
Abstract
PURPOSE To evaluate the added value of 18F-Fluorocholine (18F-FCH) PET/CT in presurgical imaging of patients with primary hyperparathyroidism (HPT) and challenging localization of the hyper-functioning parathyroid glands. METHODS We included 27 consecutive patients with primary HPT (19 F; median age: 58 years), with either (i) non-conclusive pre-surgical localization with 99mTc-sestaMIBI scintigraphy and neck ultrasonography (US), (ii) recurrence of previously operated HPT, or (iii) familiar HPT with a suspicion of multiple gland disease. Histological findings and resolution of HPT were considered as the gold standard. RESULTS 18F-FCH PET/CT was positive in 24/27 patients. Twenty-one patients underwent surgery with 27 resected lesions (14 adenomas, 11 hyperplastic glands, two hyper-functioning histologically normal glands), with resolution of HPT in 19/21 patients (90%). 18F-FCH PET/CT localized 22 lesions in 17/21 patients (per patient: sensitivity 81%, positive predictive value (PPV) 94%; per gland: sensitivity 76%, PPV 85%, specificity 91%, negative predictive value (NPV) 86%). 18F-FCH PET/CT found eight lesions which were undetectable on both 99mTc-sestaMIBI scintigraphy and US. In patients with a familial HPT and/or a multiple gland disease, sensitivity was 100 and 79% on a per-patient and a per-gland analysis respectively, while NPV was 63%. In six patients with a persistence or recurrence of previously treated HPT, 18F-FCH PET/CT localized all lesions, both in sporadic and familiar disease. CONCLUSIONS 18F-FCH PET/CT is a promising modality in challenging pre-surgical localization of hyper-functioning parathyroid glands, such as inconclusive standard imaging, recurrence after surgery, or suspected multiple gland disease.
Collapse
Affiliation(s)
- Serena Grimaldi
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France.
| | - Jacques Young
- Department of Endocrinology, Université Paris Sud, Assistance Publique-Hôpitaux de Paris, Bicetre Hospital and INSERM U1185, 78 rue du Général Leclercq, 94275, Le Kremlin Bicêtre, France
| | - Peter Kamenicky
- Department of Endocrinology, Université Paris Sud, Assistance Publique-Hôpitaux de Paris, Bicetre Hospital and INSERM U1185, 78 rue du Général Leclercq, 94275, Le Kremlin Bicêtre, France
| | - Dana Hartl
- Division of Surgical Oncology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Marie Terroir
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France
| | - Sophie Leboulleux
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France
| | - Amandine Berdelou
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France
| | - Julien Hadoux
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France
| | - Segolene Hescot
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France
| | - Hervé Remy
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France
| | - Eric Baudin
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France
| | - Martin Schlumberger
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France
| | - Désirée Deandreis
- Nuclear Medicine and Endocrine Tumors, Gustave Roussy, 94800, Villejuif, France.,Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, corso Bramante 88, 10126, Torino, Italy
| |
Collapse
|